在精神病学中实施药物遗传学的新干预措施:对PSY-PGx临床研究的描述
Teuntje A D Pelgrim1, Alexandra Philipsen2, Allan H Young3
1Department of Psychiatry, Parnassia Psychiatric Institute, 1062HN Amsterdam, The Netherlands.
Pharmaceuticals (Basel, Switzerland)
|February 24, 2024
概括
使用药物遗传学,以CYP2C19和CYP2D6代谢器状态为指导的个性化精神病治疗显示出改善患者康复和减少抗抑郁药和抗精神病药物的试验和错误处方的希望.
科学领域:
- 精神病学药物基因组学
- 在心理健康领域的精准医学.
- 临床试验方法论 临床试验方法论
背景情况:
- 目前的精神病药物治疗仅在三分之一的患者中有效,通常是由于副作用和漫长的试错过程.
- 在精神病学中,对个性化医学的需求对于改善治疗结果至关重要.
- 现有的治疗模式强调了新的,个性化的方法的紧迫性.
研究的目的:
- 根据CYP2C19和CYP2D6代谢器状态,研究调整抗抑郁药 (埃斯卡托普拉姆,塞特拉林) 和抗精神病药 (里斯佩里,阿里皮普拉) 剂量的有效性.
- 评估药物遗传学导向剂量对情绪,焦虑和精神疾病患者个人康复和临床结果的影响.
- 评估二次结果,包括副作用,幸福感,数字表型和心理社会功能.
主要方法:
- 一个前性,患者和评价者盲目的,随机对照试验,涉及9个国际站点的2500名患者.
- 在24周的治疗期内随机分配到药物遗传学导向剂量组或标准剂量组.
- 主要结果通过使用康复评估量表 (RAS-DS) 测量个人康复;次要结果包括临床反应,缓解,副作用和功能.
主要成果:
- 该部分应在研究完成并获得结果后填写.
- 这项研究旨在提供关于药物遗传测试在精神病治疗中的有用性的可靠数据.
- 预期的发现将为个性化治疗策略提供信息.
结论:
- 这是首个国际性的,多中心的,非行业赞助的随机对照试验在精神病学药物遗传学.
- 这项研究旨在提供关键的见解,对药物遗传学引导治疗精神疾病的有效性和实用性.
- 结果将整合到现有的剂量指南中,以推进个性化精神病治疗.
相关概念视频
Human Genetics
569
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
569
Psychosis: Goals of Pharmacotherapy
130
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
130
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
137
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
137
Genome-wide Association Studies-GWAS
13.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.4K
Analysis of Population Pharmacokinetic Data
256
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
256
Drug Therapy
44
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
44


